Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11670.0
(-0.51%)
KRW 11670.0
(-0.51%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 632.02 Million KRW | 152.87% |
| 2022 | 249.93 Million KRW | -85.48% |
| 2021 | 1.72 Billion KRW | -21.41% |
| 2020 | 2.18 Billion KRW | 40.3% |
| 2019 | 1.56 Billion KRW | 0.0% |
| 2018 | - KRW | 0.0% |
| 2017 | - KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| 2015 | - KRW | 0.0% |
| 2014 | - KRW | 0.0% |
| 2013 | - KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| 2011 | - KRW | 0.0% |
| 2010 | - KRW | 0.0% |
| 2009 | - KRW | 0.0% |
| 2008 | - KRW | -100.0% |
| 2007 | 40.04 Million KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 600.87 Million KRW | -2.36% |
| 2024 Q1 | 615.37 Million KRW | -2.63% |
| 2023 FY | 632.02 Million KRW | 152.87% |
| 2023 Q4 | 632.02 Million KRW | 15.42% |
| 2023 Q3 | 547.58 Million KRW | -10.86% |
| 2023 Q2 | 614.32 Million KRW | 110.46% |
| 2023 Q1 | 291.89 Million KRW | 16.79% |
| 2022 Q3 | 296.57 Million KRW | -24.44% |
| 2022 Q2 | 392.5 Million KRW | -16.24% |
| 2022 FY | 249.93 Million KRW | -85.48% |
| 2022 Q4 | 249.93 Million KRW | -15.72% |
| 2022 Q1 | 468.58 Million KRW | -72.77% |
| 2021 Q3 | 1.85 Billion KRW | -5.6% |
| 2021 FY | 1.72 Billion KRW | -21.41% |
| 2021 Q1 | 2.07 Billion KRW | -5.07% |
| 2021 Q2 | 1.96 Billion KRW | -5.47% |
| 2021 Q4 | 1.72 Billion KRW | -7.23% |
| 2020 FY | 2.18 Billion KRW | 40.3% |
| 2020 Q1 | 1.48 Billion KRW | -5.05% |
| 2020 Q2 | 1.64 Billion KRW | 11.11% |
| 2020 Q3 | 1.52 Billion KRW | -7.35% |
| 2020 Q4 | 2.18 Billion KRW | 43.52% |
| 2019 Q1 | 529.23 Million KRW | 0.0% |
| 2019 FY | 1.56 Billion KRW | 0.0% |
| 2019 Q4 | 1.56 Billion KRW | -6.53% |
| 2019 Q3 | 1.66 Billion KRW | -7.3% |
| 2019 Q2 | 1.8 Billion KRW | 240.4% |
| 2018 Q2 | - KRW | 0.0% |
| 2018 FY | - KRW | 0.0% |
| 2018 Q4 | - KRW | 0.0% |
| 2018 Q3 | - KRW | 0.0% |
| 2018 Q1 | - KRW | 0.0% |
| 2017 FY | - KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2017 Q4 | - KRW | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2016 Q3 | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| 2016 Q2 | - KRW | 0.0% |
| 2015 Q4 | - KRW | 0.0% |
| 2015 Q1 | - KRW | 0.0% |
| 2015 Q3 | - KRW | 0.0% |
| 2015 Q2 | - KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| 2014 Q4 | - KRW | 0.0% |
| 2014 FY | - KRW | 0.0% |
| 2014 Q3 | - KRW | 0.0% |
| 2014 Q2 | - KRW | 0.0% |
| 2014 Q1 | - KRW | 0.0% |
| 2013 Q4 | - KRW | 0.0% |
| 2013 FY | - KRW | 0.0% |
| 2013 Q1 | - KRW | 0.0% |
| 2013 Q2 | - KRW | 0.0% |
| 2013 Q3 | - KRW | 0.0% |
| 2012 Q1 | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 Q2 | - KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q3 | - KRW | 0.0% |
| 2011 Q2 | - KRW | 0.0% |
| 2011 Q1 | - KRW | 0.0% |
| 2011 Q3 | - KRW | 0.0% |
| 2011 FY | - KRW | 0.0% |
| 2011 Q4 | - KRW | 0.0% |
| 2010 Q3 | - KRW | 0.0% |
| 2010 Q2 | - KRW | 0.0% |
| 2010 Q4 | - KRW | 0.0% |
| 2010 Q1 | - KRW | 0.0% |
| 2010 FY | - KRW | 0.0% |
| 2009 Q3 | - KRW | 0.0% |
| 2009 FY | - KRW | 0.0% |
| 2009 Q2 | - KRW | 0.0% |
| 2009 Q1 | - KRW | 0.0% |
| 2009 Q4 | - KRW | 0.0% |
| 2008 Q2 | - KRW | -100.0% |
| 2008 Q3 | - KRW | 0.0% |
| 2008 Q4 | - KRW | 0.0% |
| 2008 FY | - KRW | -100.0% |
| 2008 Q1 | 29.45 Million KRW | -26.45% |
| 2007 Q3 | 50.46 Million KRW | -16.89% |
| 2007 Q4 | 40.04 Million KRW | -20.65% |
| 2007 FY | 40.04 Million KRW | 0.0% |
| 2007 Q1 | 70.82 Million KRW | 0.0% |
| 2007 Q2 | 60.72 Million KRW | -14.26% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 98.69% |
| Yuhan Corporation | 230.07 Billion KRW | 99.725% |
| Yuhan Corporation | 230.07 Billion KRW | 99.725% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 98.396% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 98.396% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 98.396% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 99.835% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 99.641% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 99.909% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.629% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.629% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.629% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -6.136% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 99.865% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | 98.539% |
| HANDOK Inc. | 300.01 Billion KRW | 99.789% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 99.635% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | 97.939% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 99.204% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 99.651% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -165.416% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 99.567% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 99.055% |
| Boryung Corporation | 204.21 Billion KRW | 99.691% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | 98.388% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 99.467% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 99.258% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 99.258% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 99.865% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 99.732% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | 51.026% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 99.301% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 98.631% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 98.631% |
| Korea United Pharm Inc. | 40.33 Billion KRW | 98.433% |
| CKD Bio Corp. | 146.92 Billion KRW | 99.57% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 99.865% |
| JW Holdings Corporation | 554.58 Billion KRW | 99.886% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 99.719% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 99.89% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 99.845% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 99.712% |
| JW Lifescience Corporation | 46.31 Billion KRW | 98.635% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 99.71% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 99.256% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | 97.618% |